ADC Therapeutics SA ADCT
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
ADC Therapeutics SA (ADCT) is a healthcare company listed in the US with a market value of about $171M. In the twelve months to September 30, 2026 it had revenue of $85M and net income of -$81M, a net margin of -95.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -73%.
About ADC Therapeutics SA
ADC Therapeutics SA is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $1M in 2018 to $81M in 2025, growth of about 84.0% a year. It was profitable in 0 of the last 8 years in our data. It spends 128% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85M | $81M | $71M | $70M | $210M | $34M | $0 | $2M | $1M |
| Net income | -$81M | -$143M | -$158M | -$240M | -$157M | -$230M | -$246M | -$116M | -$123M |
| Free cash flow | -$101M | -$141M | -$125M | -$122M | -$139M | -$237M | -$170M | -$122M | -$122M |
| EPS (diluted) | $-0.46 | $-1.12 | $-1.24 | $-1.88 | $-1.23 | $-1.80 | $-1.93 | $-0.91 | $-0.96 |
| Net margin | -95.7% | -175.3% | -222.8% | -345.1% | -74.9% | -678.2% | — | -4977.9% | -10797.9% |
| ROIC | — | — | — | — | -49.5% | -96.6% | -46.3% | -84.9% | -78.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does ADC Therapeutics SA pay a dividend?
Not currently.
Is ADC Therapeutics SA a good stock to buy?
We do not give buy or sell advice. ADC Therapeutics SA scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.